Telix Pharmaceuticals Ltd (ASX: TLX) shares have been strong performers over the past month.
Since this time in March, the radiopharmaceuticals company’s shares are up over 30%.
As a comparison, the ASX 200 index is up 1.5% over the same period.
The good news is that the rebound in the Telix share price may not be over according to analysts at Bell Potter.
Let’s see what they are saying about the company behind Illuccix and Gozellix products.
What is the broker saying?
Bell Potter highlights that Telix has released a first-quarter sales update which revealed that Illuccix continues to win market share. It said:
TLX reported a pleasing jump in 1Q26 revenues to $US230m driven by a 16% sequential quarter increase in PSMA imaging revenues to US$186m. This was the result the company had been seeking in 4Q25 following the refresh on pass through pricing (for Gozellix) that had come into effect from 1 October.
For the March quarter, US dose volume increased 5%, implying that TLX successfully converted more of its hospital customer base to the higher reimbursed Gozellix product which services the Medicare fee for service market in the US, while Illuccix continues to be ordered by other clients where the higher reimbursement is not relevant due to the clientele mix.
The broker was also pleased to see Telix reaffirm its guidance for FY 2026. It believes this guidance is achievable based on its positive start to the year, with PSMA revenues comfortably ahead of consensus expectations. It adds:
1Q26 PSMA revenues were ~7% ahead of consensus. FY26 revenue guidance for US$950m – US$970m is re-affirmed. The bottom end of the guidance requires TLX to achieve avg qtly revenues of US$240m â not unreasonable given the short term competitive outlook and strong 1Q26 top line result.
Telix shares tipped to rise
According to the note, the broker has retained its buy rating and $19.00 price target on Telix shares.
Based on its current share price of $13.58, this implies potential upside of 40% for investors between now and this time next year.
Commenting on its buy recommendation, Bell Potter said:
The company continues to make good progress on multiple pipeline products. Short term news flow includes acceptance by the FDA of the resubmitted NDA for Pixclara and the amendment to the IND for TLX591 (prostate cancer Tx). We maintain our Buy rating. FY26 EBITDA is increased by ~US$21m to US$55.3m.
The post Why rebounding Telix shares could still rise 40% appeared first on The Motley Fool Australia.
Should you invest $1,000 in Telix Pharmaceuticals right now?
Before you buy Telix Pharmaceuticals shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Telix Pharmaceuticals wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Why Bank of Queensland, Guzman Y Gomez, NextDC, and Telix shares are racing higher today
- Are Telix shares a buy after flying 40% higher in March?
- Why is everyone talking about Telix, Bank of Queensland and NextDC shares today?
- Why are Telix shares jumping 8% today?
- Telix Pharmaceuticals Q1 2026: Revenue growth, guidance reaffirmed
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.